Morten Graugaard
Morten Graugaard is the CEO of Orbis Medicines, a biotechnology company transforming potent biologic therapies into more accessible, orally delivered macrocycle medicines. He brings more than 20 years of leadership experience across venture investing, R&D, business development, M&A and company building.
Before joining Orbis full-time, Morten served as its board chair and was previously a partner at Novo Holdings, where he led Novo Seeds and helped launch and scale multiple high-impact biotech companies, including Orbis Medicines.
Under his leadership, Orbis has raised more than €116 million to advance its AI-enabled discovery platform and pipeline of next-generation oral macrocycles designed to replace injectable biologics. Morten holds an MSc in human biology from the University of Copenhagen and has served on the boards of several biotechs including Muna Therapeutics, NMD Pharma, Syndesi Therapeutics and Acesion Pharma.
ArticleDisrupting the biologics market through innovations in macrocycle R&D
New macrocycle technologies are turning a once difficult drug class into a scalable engine for developing potent oral therapies.